(ABT) Abbott Laboratories - Ratings and Ratios
Pharmaceuticals, Diagnostics, Nutritionals, MedicalDevices
ABT EPS (Earnings per Share)
ABT Revenue
Description: ABT Abbott Laboratories
Abbott Laboratories is a diversified healthcare company with a presence in multiple segments, including pharmaceuticals, diagnostics, nutritionals, and medical devices. The companys pharmaceutical segment offers a range of generic medications for various conditions, while its diagnostics segment provides laboratory and transfusion medicine systems, molecular diagnostics, and point-of-care testing solutions. Its nutritional products cater to pediatric and adult needs, and its medical devices segment offers solutions for cardiovascular diseases, diabetes care, and neuromodulation.
From a financial perspective, Abbott Laboratories has demonstrated strong performance, with a Return on Equity (RoE) of 30.76%. To further analyze the companys financial health, we can look at additional KPIs such as Revenue Growth, Operating Margin, and Debt-to-Equity ratio. Assuming the companys revenue growth is stable, an operating margin above 20% indicates a strong ability to maintain profitability. A Debt-to-Equity ratio below 0.5 suggests a healthy balance between debt and equity financing.
In terms of valuation, Abbott Laboratories has a Price-to-Earnings (P/E) ratio of 17.35, which is relatively reasonable compared to its peers in the healthcare equipment industry. The Forward P/E ratio of 25.84 suggests that the market expects the companys earnings to grow in the future. To further assess the companys valuation, we can consider metrics such as Enterprise Value-to-EBITDA (EV/EBITDA) and Price-to-Book (P/B) ratio. An EV/EBITDA below 15 and a P/B ratio below 4 may indicate a relatively undervalued stock.
From a technical analysis perspective, the stocks current price is near its support level of 131.8, indicating a potential buying opportunity. The companys market capitalization is substantial, standing at $232.44 billion, which can contribute to liquidity and stability. To further analyze the stocks technicals, we can examine indicators such as the Relative Strength Index (RSI) and Moving Average Convergence Divergence (MACD). An RSI below 30 may indicate oversold conditions, while a MACD crossover above the signal line could be a bullish sign.
ABT Stock Overview
| Market Cap in USD | 231,150m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1978-01-13 |
ABT Stock Ratings
| Growth Rating | 59.4% |
| Fundamental | 80.5% |
| Dividend Rating | 64.0% |
| Return 12m vs S&P 500 | -2.0% |
| Analyst Rating | 4.11 of 5 |
ABT Dividends
| Dividend Yield 12m | 1.77% |
| Yield on Cost 5y | 2.40% |
| Annual Growth 5y | 8.85% |
| Payout Consistency | 98.2% |
| Payout Ratio | 47.4% |
ABT Growth Ratios
| Growth Correlation 3m | -23.7% |
| Growth Correlation 12m | 74.7% |
| Growth Correlation 5y | 30.7% |
| CAGR 5y | 11.00% |
| CAGR/Max DD 3y | 0.53 |
| CAGR/Mean DD 3y | 2.04 |
| Sharpe Ratio 12m | 0.90 |
| Alpha | -1.22 |
| Beta | 0.785 |
| Volatility | 21.24% |
| Current Volume | 5698.9k |
| Average Volume 20d | 4806.5k |
| Stop Loss | 129.7 (-3%) |
| Signal | 1.46 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (13.98b TTM) > 0 and > 6% of Revenue (6% = 2.59b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 0.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 25.58% (prev 22.98%; Δ 2.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 9.04b <= Net Income 13.98b (YES >=105%, WARN >=100%) |
| Net Debt (6.49b) to EBITDA (11.61b) ratio: 0.56 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.75b) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 52.79% (prev 50.63%; Δ 2.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.91% (prev 55.77%; Δ -0.86pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 14.78 (EBITDA TTM 11.61b / Interest Expense TTM 573.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.59
| (A) 0.13 = (Total Current Assets 24.47b - Total Current Liabilities 13.44b) / Total Assets 84.00b |
| (B) 0.58 = Retained Earnings (Balance) 48.47b / Total Assets 84.00b |
| (C) 0.11 = EBIT TTM 8.47b / Avg Total Assets 78.51b |
| (D) 2.03 = Book Value of Equity 67.17b / Total Liabilities 33.17b |
| Total Rating: 5.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.52
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 2.85% = 1.43 |
| 3. FCF Margin 15.72% = 3.93 |
| 4. Debt/Equity 0.27 = 2.47 |
| 5. Debt/Ebitda 1.16 = 1.54 |
| 6. ROIC - WACC 14.23% = 12.50 |
| 7. RoE 29.93% = 2.49 |
| 8. Rev. Trend 69.36% = 3.47 |
| 9. Rev. CAGR 2.50% = 0.31 |
| 10. EPS Trend 41.73% = 1.04 |
| 11. EPS CAGR 8.42% = 0.84 |
What is the price of ABT shares?
Over the past week, the price has changed by +0.59%, over one month by +2.07%, over three months by -1.55% and over the past year by +16.67%.
Is Abbott Laboratories a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABT is around 127.95 USD . This means that ABT is currently overvalued and has a potential downside of -4.32%.
Is ABT a buy, sell or hold?
- Strong Buy: 12
- Buy: 7
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 142.5 | 6.5% |
| Analysts Target Price | 142.5 | 6.5% |
| ValueRay Target Price | 143.2 | 7.1% |
Last update: 2025-09-06 05:00
ABT Fundamental Data Overview
CCE Cash And Equivalents = 6.95b USD (last quarter)
P/E Trailing = 16.5805
P/E Forward = 23.2558
P/S = 5.362
P/B = 4.5497
P/EG = 4.1675
Beta = 0.688
Revenue TTM = 43.11b USD
EBIT TTM = 8.47b USD
EBITDA TTM = 11.61b USD
Long Term Debt = 12.93b USD (from longTermDebt, last quarter)
Short Term Debt = 507.0m USD (from shortTermDebt, last quarter)
Debt = 13.44b USD (Calculated: Short Term 507.0m + Long Term 12.93b)
Net Debt = 6.49b USD (from netDebt column, last quarter)
Enterprise Value = 237.64b USD (231.15b + Debt 13.44b - CCE 6.95b)
Interest Coverage Ratio = 14.78 (Ebit TTM 8.47b / Interest Expense TTM 573.0m)
FCF Yield = 2.85% (FCF TTM 6.78b / Enterprise Value 237.64b)
FCF Margin = 15.72% (FCF TTM 6.78b / Revenue TTM 43.11b)
Net Margin = 32.43% (Net Income TTM 13.98b / Revenue TTM 43.11b)
Gross Margin = 52.79% ((Revenue TTM 43.11b - Cost of Revenue TTM 20.35b) / Revenue TTM)
Tobins Q-Ratio = 3.54 (Enterprise Value 237.64b / Book Value Of Equity 67.17b)
Interest Expense / Debt = 0.90% (Interest Expense 121.0m / Debt 13.44b)
Taxrate = -91.10% (set to none) (-6.39b / 7.01b)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.82 (Total Current Assets 24.47b / Total Current Liabilities 13.44b)
Debt / Equity = 0.27 (Debt 13.44b / last Quarter total Stockholder Equity 50.56b)
Debt / EBITDA = 1.16 (Net Debt 6.49b / EBITDA 11.61b)
Debt / FCF = 1.98 (Debt 13.44b / FCF TTM 6.78b)
Total Stockholder Equity = 46.71b (last 4 quarters mean)
RoA = 16.64% (Net Income 13.98b, Total Assets 84.00b )
RoE = 29.93% (Net Income TTM 13.98b / Total Stockholder Equity 46.71b)
RoCE = 14.20% (Ebit 8.47b / (Equity 46.71b + L.T.Debt 12.93b))
RoIC = 14.23% (Ebit 8.47b / (Assets 84.00b - Current Assets 24.47b))
WACC = unknown (E(231.15b)/V(244.59b) * Re(8.91%)) + (D(13.44b)/V(244.59b) * Rd(0.90%) * (1-Tc(none)))
Shares Correlation 3-Years: -55.39 | Cagr: -0.07%
Discount Rate = 8.91% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 73.93% ; FCFE base≈6.33b ; Y1≈5.88b ; Y5≈5.38b
Fair Price DCF = 47.53 (DCF Value 82.72b / Shares Outstanding 1.74b; 5y FCF grow -9.03% → 3.0% )
Revenue Correlation: 69.36 | Revenue CAGR: 2.50%
Rev Growth-of-Growth: 4.52
EPS Correlation: 41.73 | EPS CAGR: 8.42%
EPS Growth-of-Growth: 23.76
Additional Sources for ABT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle